Title:
CLEARING AGENT
Document Type and Number:
WIPO Patent Application WO/2018/097239
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a clearing agent which is capable of, after administering a fusant of a streptavidin mutant with a molecular probe, preventing the localization of the fusant at a target site such as a disease site and quickly removing (clearing) the fusant, which remains in the body, from the body. According to the present invention, provided is a compound represented by formula (1) or a salt thereof. [In formula (1): X1a, X1b, X2a and X2b independently represent O or NH; Y1 and Y2 independently represent C or S; Z1 and Z2 independently represent O, S or NH; V1 and V2 independently represent S or S+-O-; n1 and n2 independently represent an integer of 0 or 1; L10 and L12 independently represent a divalent linking group; L11 represents a trivalent linking group; L14 represents a divalent linking group; and Sugar represents a sugar residue.]
More Like This:
Inventors:
TSUKAGOSHI MASANOBU (JP)
Application Number:
PCT/JP2017/042190
Publication Date:
May 31, 2018
Filing Date:
November 24, 2017
Export Citation:
Assignee:
SAVID THERAPEUTICS INC (JP)
International Classes:
C07H15/26; A61K51/04; A61K51/08; C07D519/00; C07K14/36
Domestic Patent References:
| WO2015125820A1 | 2015-08-27 | |||
| WO2010095455A1 | 2010-08-26 | |||
| WO2015125820A1 | 2015-08-27 | |||
| WO2008047723A1 | 2008-04-24 |
Foreign References:
| JP2012167987A | 2012-09-06 | |||
| US5608060A | 1997-03-04 | |||
| US7626011B2 | 2009-12-01 |
Other References:
WILBUR, D. S. ET AL.: "Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants", BIOCONJUGATE CHEMISTRY, vol. 21, no. 7, 2010, pages 1225 - 1238, XP055221504
HNATOWICH, J. NUCL. MED., vol. 28, 1987, pages 1294 - 1302
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
LEE ET AL.: "have conducted humanization of an anti-epiregulin antibody and evaluation thereof", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 444, 2013, pages 1011 - 1017
WANG ET AL., JOURNAL OF BACTERIOLOGY, vol. 196, 2014, pages 3122
WILBUR ET AL., BIOCONJUGATE.CHEM., vol. 21, 2010, pages 1225
See also references of EP 3546470A4
HNATOWICH, J. NUCL. MED., vol. 28, 1987, pages 1294 - 1302
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
LEE ET AL.: "have conducted humanization of an anti-epiregulin antibody and evaluation thereof", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 444, 2013, pages 1011 - 1017
WANG ET AL., JOURNAL OF BACTERIOLOGY, vol. 196, 2014, pages 3122
WILBUR ET AL., BIOCONJUGATE.CHEM., vol. 21, 2010, pages 1225
See also references of EP 3546470A4
Attorney, Agent or Firm:
SIKS & CO. (JP)
Download PDF:
Previous Patent: LIGHT MODULATION ELEMENT AND INFORMATION RECORDING MEDIUM
Next Patent: LASER DEVICE AND LIGHT-SOURCE DEVICE
Next Patent: LASER DEVICE AND LIGHT-SOURCE DEVICE